BRPI0619364A2 - métodos para a profilaxia de uma condição intestinal e para o tratamento de uma condição intestinal, e, cepa bacteriana isolada - Google Patents

métodos para a profilaxia de uma condição intestinal e para o tratamento de uma condição intestinal, e, cepa bacteriana isolada Download PDF

Info

Publication number
BRPI0619364A2
BRPI0619364A2 BRPI0619364-1A BRPI0619364A BRPI0619364A2 BR PI0619364 A2 BRPI0619364 A2 BR PI0619364A2 BR PI0619364 A BRPI0619364 A BR PI0619364A BR PI0619364 A2 BRPI0619364 A2 BR PI0619364A2
Authority
BR
Brazil
Prior art keywords
bacillus
bacteria
treatment
diarrhea
clostridium difficile
Prior art date
Application number
BRPI0619364-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Benedikt Sas
Hemel Johan Van
Jan Vandenkerckhove
Eric Peys
Hai Meng Tan
Chea-Yun Se
Jerry Varghese
Original Assignee
Kemin Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Ind Inc filed Critical Kemin Ind Inc
Publication of BRPI0619364A2 publication Critical patent/BRPI0619364A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0619364-1A 2005-11-29 2006-11-29 métodos para a profilaxia de uma condição intestinal e para o tratamento de uma condição intestinal, e, cepa bacteriana isolada BRPI0619364A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74051805P 2005-11-29 2005-11-29
US60/740,518 2005-11-29
PCT/US2006/045755 WO2007064741A2 (en) 2005-11-29 2006-11-29 The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases

Publications (1)

Publication Number Publication Date
BRPI0619364A2 true BRPI0619364A2 (pt) 2011-09-27

Family

ID=38092773

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0619364-1A BRPI0619364A2 (pt) 2005-11-29 2006-11-29 métodos para a profilaxia de uma condição intestinal e para o tratamento de uma condição intestinal, e, cepa bacteriana isolada

Country Status (13)

Country Link
US (1) US20080057047A1 (https=)
EP (1) EP1956914B1 (https=)
JP (2) JP5280854B2 (https=)
KR (1) KR101470352B1 (https=)
CN (1) CN101448398B (https=)
AU (1) AU2006320613B2 (https=)
BR (1) BRPI0619364A2 (https=)
CA (1) CA2631289C (https=)
IL (1) IL191795A (https=)
NZ (1) NZ569244A (https=)
RU (1) RU2412241C2 (https=)
WO (1) WO2007064741A2 (https=)
ZA (1) ZA200804646B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2009293213C1 (en) * 2008-09-17 2015-04-30 Bayer Cropscience Lp Method for using a Bacillus subtilis strain to enhance animal health
CN102369105A (zh) * 2008-09-24 2012-03-07 莱斯勒斯公司 在材料中引入耐热和/或耐压生物
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
WO2011111783A1 (ja) * 2010-03-12 2011-09-15 カルピス株式会社 大腸におけるビフィズス菌の増加及び減少抑制剤
EP2547348B1 (en) 2010-03-17 2015-05-20 Bayer Cropscience LP Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
WO2012009712A2 (en) 2010-07-16 2012-01-19 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
WO2012092469A2 (en) * 2010-12-29 2012-07-05 Cangene Corporation Clostridium difficile antigens
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
WO2014022572A1 (en) 2012-08-01 2014-02-06 Pacific Vet Group-Usa, Inc. Probiotic for amelioration of coccidiosis vaccine reaction
RU2534356C2 (ru) * 2012-10-04 2014-11-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Россельхозакадемии (ГНУ ИЭВСиДВ Россельхозакадемии) Способ контроля качества дезинфекции птицеводческих помещений
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
FR3007655B1 (fr) * 2013-06-28 2016-12-23 Lesaffre & Cie Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora
AU2015292271B2 (en) * 2014-07-25 2020-09-10 The University Of Queensland Bacillus amyloliquefaciens probiotic compositions, methods of production, and methods of use
CA3000621C (en) 2014-09-30 2024-02-27 Auburn University Use of pectin or pectin-related saccharides to enhance efficacy of plant growth-promoting rhizobacteria (pgpr) strains for promoting growth and health in plants and animals
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
JP6595761B2 (ja) * 2014-12-19 2019-10-23 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
AU2016209132B2 (en) * 2015-01-23 2021-07-01 Novozymes A/S Bacillus strains improving health and performance of production animals
US11331351B2 (en) 2015-01-23 2022-05-17 Novozymes A/S Bacillus strains improving health and performance of production animals
EP3261653B1 (en) 2015-01-23 2019-10-09 Novozymes A/S Bacillus subtilis subspecies
WO2016194427A1 (ja) * 2015-05-30 2016-12-08 日環科学株式会社 プロバイオティクス、あるいはプレバイオティクス、並びにその製造方法、微生物製剤、健康食品並びに医薬品
WO2017062175A1 (en) 2015-10-06 2017-04-13 Albert Einstein College Of Medicine, Inc. Microbial hyperswarmers and uses thereof
CN108347974B (zh) * 2015-10-26 2023-01-10 希杰维康株式会社 解淀粉芽孢杆菌菌株、谷物发酵物、其制备方法及其应用
RU2641979C1 (ru) * 2016-10-24 2018-01-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Способ морфологической оценки влияния различных лекарственных форм железа для энтерального применения на тонкий отдел кишечника у экспериментальных животных
JP7104078B2 (ja) * 2017-06-30 2022-07-20 エボニック オペレーションズ ゲーエムベーハー プロバイオティクス活性がある枯草菌株
US20190289878A1 (en) * 2018-03-23 2019-09-26 Purina Animal Nutrition Llc Methods of feeding animals feed products containing direct-fed microbials
EP3801578B1 (en) * 2018-06-07 2023-08-30 Artugen Therapeutics Ltd. B. amyloliquefaciens strain and therapeutic use
JP7634884B2 (ja) * 2019-05-14 2025-02-25 オルメンデス・ソシエテ・アノニム 活性プロバイオティクス組成物の増強または不活性プロバイオティクス組成物の活性化のためのバチルス・アミロリクエファシエンスおよび／またはバチルス・サブティリスの使用、このようにして得られた組成物、ならびに関連方法
WO2020257769A1 (en) * 2019-06-21 2020-12-24 The Board Of Trustees Of The University Of Arkansas Bacillus isolate compositions and methods of using and producing the same
GB201911925D0 (en) 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections
WO2021116983A1 (en) * 2019-12-11 2021-06-17 Artugen Therapeutics, Ltd. Edible products comprising bacterial strains and methods of use
US20210283199A1 (en) * 2020-03-13 2021-09-16 Kemin Industries, Inc. Method for controlling clostridium infection in animals
GB202013874D0 (en) * 2020-09-03 2020-10-21 Sporegen Ltd Treatment and prevention of viral infections
MX2023006676A (es) 2020-12-09 2023-07-04 Purina Animal Nutrition Llc Composiciones alimenticias y metodos para inhibir dermatitis ulcerosa focal.
CN113151069B (zh) * 2021-04-01 2022-07-26 安杰利(重庆)生物科技有限公司 一种枯草芽孢杆菌及其在制备抗菌肽、饲料中的应用
KR102546973B1 (ko) * 2021-10-20 2023-06-26 주식회사 리빙진 바실러스 밸레젠시스 Kh2-2 균주를 포함하는 면역증강용 조성물
WO2023220279A1 (en) * 2022-05-12 2023-11-16 Can Technologies, Inc. Compositions and methods for the treatment and prevention of campylobacter infection
CN115725461B (zh) * 2022-11-03 2024-03-19 东北农业大学 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用
FR3158224A1 (fr) * 2024-01-12 2025-07-18 Lesaffre Et Compagnie Effet bénéfique d’une bactérie probiotique Bacillus subtilis dans la lutte contre les infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968493A (en) * 1986-06-30 1990-11-06 American Cyanamid Company Method for controlling chronic respiratory disease, fowl cholera and necrotic enteritis in avian species
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
ZA926834B (en) * 1991-09-09 1993-03-15 American Cyanamid Co Antibiotic LL-E19020 Gamma.
TW455591B (en) * 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2879321B2 (ja) * 1996-03-14 1999-04-05 久保田 豊秋 動物用経口組成物
DE69707413T3 (de) * 1997-01-09 2009-07-02 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
RU2246537C2 (ru) * 2002-11-11 2005-02-20 Закрытое акционерное общество "КУЛ" Штамм бактерий bacillus subtilis, используемый для получения пробиотического препарата, предназначенного для профилактики и лечения желудочно-кишечных заболеваний сельскохозяйственных животных, птицы и рыбы
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
JP4189224B2 (ja) * 2003-01-14 2008-12-03 株式会社カンサイ バチルス属に属する微生物及びそれを用いる防除剤
KR100535912B1 (ko) * 2003-12-17 2005-12-09 주식회사 케이티앤지 신규한 미생물 바실러스 아밀로리쿼페이션스 케이티지비0202 및 이를 이용한 식물병원균의 방제방법
JP2005198518A (ja) * 2004-01-13 2005-07-28 Asahi Business Support Co Ltd 海苔屑分解処理法及び微生物
RU2270858C2 (ru) * 2004-03-30 2006-02-27 Институт биологии Уфимского научного центра РАН Штамм бактерий b. subtilis - продуцент сурфактина
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders

Also Published As

Publication number Publication date
RU2008121602A (ru) 2009-12-10
JP2013173750A (ja) 2013-09-05
IL191795A0 (en) 2009-02-11
EP1956914A2 (en) 2008-08-20
WO2007064741A8 (en) 2008-01-31
WO2007064741A3 (en) 2008-05-08
JP5280854B2 (ja) 2013-09-04
KR101470352B1 (ko) 2014-12-09
CA2631289A1 (en) 2007-06-07
AU2006320613B2 (en) 2012-08-16
EP1956914A4 (en) 2011-12-21
EP1956914B1 (en) 2014-01-08
US20080057047A1 (en) 2008-03-06
NZ569244A (en) 2012-07-27
RU2412241C2 (ru) 2011-02-20
CN101448398B (zh) 2013-05-08
AU2006320613A1 (en) 2007-06-07
WO2007064741A2 (en) 2007-06-07
CA2631289C (en) 2015-01-06
KR20080073771A (ko) 2008-08-11
IL191795A (en) 2013-07-31
ZA200804646B (en) 2011-11-30
JP2009519238A (ja) 2009-05-14
CN101448398A (zh) 2009-06-03

Similar Documents

Publication Publication Date Title
BRPI0619364A2 (pt) métodos para a profilaxia de uma condição intestinal e para o tratamento de uma condição intestinal, e, cepa bacteriana isolada
Stavropoulou et al. Probiotics in medicine: a long debate
AU2019282713B2 (en) Methods and compositions for the treatment of C. difficile
Hagihara et al. The impact of Clostridium butyricum MIYAIRI 588 on the murine gut microbiome and colonic tissue
KR101925508B1 (ko) 페디오코쿠스를 함유하는 의약 조성물 및 위장병 증후군의 증상을 감소시키기 위한 방법
Anadón et al. Probiotics: safety and toxicity considerations
EP4009995B1 (en) Probiotic mixture
Periti et al. Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii
US20220054558A1 (en) Compositions comprising bacterial strains
MX2008006778A (en) The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
BR122022016032B1 (pt) Composição de cepa bacteriana
HK40098932A (en) B. amyloliquefaciens strain and therapeutic use
HK40100510A (en) B. amyloliquefaciens strain and therapeutic use
Rolfe Probiotics: Prospects for use in Clostridium difficile-associated intestinal disease
HK40047668A (en) B. amyloliquefaciens strain and therapeutic use
HK40047668B (en) B. amyloliquefaciens strain and therapeutic use

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.